Cellyan Biotechnology Co Ltd is an integrated pharmaceutical cross-border e-commerce supply chain service provider with a professional team and related pharmaceutical storage facilities in Hong Kong... Show more
Cellyan Biotechnology Co., Ltd is a Nasdaq-listed common stock, not a fund. The company, based in Yau Tong, Hong Kong, provides OTC pharmaceutical cross-border procurement, distribution, and e-commerce supply chain services connecting Hong Kong and Mainland China. Its operations are organized into two main divisions: supply chain services, conducted through its Joint Cross Border subsidiary, and procurement and distribution, conducted through V-Alliance.
The company is a micro-capitalization issuer with a small workforce — approximately 27 full-time employees — and a modest revenue base in the low tens of millions of dollars, while reporting a net loss on a trailing basis. Ownership is highly concentrated among insiders and founding shareholders, and institutional ownership is minimal. Because there is no underlying index, no portfolio of holdings, and no expense ratio, HKPD behaves like a single small-cap equity rather than a diversified basket, which helps explain its pronounced, high-volatility price swings.
Over the last 30 days, HKPD has fallen approximately 31%, from a close near $2.04 to a latest price near $1.40. The move was not a smooth, gradual decline; rather, it unfolded in a series of sharp downlegs punctuated by brief, shallow rebounds, consistent with thin trading and elevated volatility.
The quarterly picture is considerably worse. About three months ago the shares traded near $8.32, meaning the stock has lost roughly 83% of its value over the quarter. A single-session collapse in early September, marked by a surge in volume, marked the start of the most severe leg of the drawdown, after which the shares continued to erode in a stair-step pattern toward current levels.
The most significant drivers are company-specific rather than sector-wide. The firm delayed its annual report filing (20-F), which raised governance and disclosure concerns and weighed on investor confidence. Compounding this, the stock has been subject to Nasdaq minimum-bid-price compliance requirements, creating an overhang tied to potential delisting risk.
These factors interact with the stock's micro-cap structure: a small float, low average liquidity, and concentrated ownership mean relatively modest selling pressure can produce outsized percentage moves. Broader healthcare and pharmaceutical distribution trends have been secondary to these idiosyncratic pressures, and there is little evidence that the recent decline reflects a broad deterioration in the sector rather than company-specific stress.
The three-month trend reflects a sustained de-rating driven by recurring disclosure and listing-compliance issues. The sharp early-September selloff on unusually heavy volume marked a decisive repricing of risk, after which the shares failed to establish a durable base. The absence of meaningful institutional sponsorship and a limited track record as a public company — the stock listed in January 2025 — left the shares vulnerable to continued selling.
From a macro perspective, conditions facing small-cap and foreign private issuers, including tighter liquidity and heightened scrutiny of listing compliance, provided an unfavorable backdrop. However, the magnitude of HKPD's decline is best explained by issuer-specific fundamentals and structure rather than a broad sector rotation or macroeconomic shift.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. It is designed to surface trending securities, breakout candidates, and new trading opportunities more efficiently than manual screening, while allowing users to apply customizable filters across industries and risk profiles. For investors monitoring micro-cap and small-cap equities such as HKPD, the platform offers a systematic way to compare volatility, momentum, and fundamental signals across a broad universe. Explore the AI Screener to refine your research workflow.
Investors should monitor several company-specific and structural factors in the months ahead. The resolution of the delayed 20-F filing and the restoration of timely financial reporting will be critical, as will the company's progress toward regaining compliance with Nasdaq's minimum-bid-price requirement. Any reverse share split or additional grace-period developments would be significant events to track.
Beyond compliance, attention should focus on revenue trends in the OTC pharmaceutical cross-border e-commerce business, margin and cash-flow trajectory given the current net-loss position, and any changes in the concentrated insider ownership structure. Macroeconomic considerations — including China cross-border e-commerce demand, logistics costs, and regulatory developments affecting pharmaceutical distribution — also warrant monitoring. These factors, rather than broad market direction, are likely to remain the dominant influences on HKPD over the coming months.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HKPD saw its Momentum Indicator move below the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator turned negative. In 26 of the 27 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HKPD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for HKPD entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HKPD's RSI Indicator exited the oversold zone, 12 of 14 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +15.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where HKPD advanced for three days, in 57 of 65 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
HKPD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.566) is normal, around the industry mean (14.423). P/E Ratio (6.136) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (0.147) is also within normal values, averaging (4.260).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. HKPD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HKPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalDistributors